Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) - Vaxcyte, Inc. $ in Thousands |
6 Months Ended |
|---|---|
|
Jun. 30, 2026
USD ($)
| |
| Deferred Royalty Obligation [Line Items] | |
| Liability related to sale of future Vaxcyte royalties - beginning balance | $ 219,536 |
| Non-cash interest expense associated with the sale of future Vaxcyte royalties | 19,329 |
| Amortization of issuance costs | 199 |
| Liability related to the sale of future Vaxcyte royalties - ending balance | $ 239,064 |